Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Smoking was Associated With Poor Response to Intravenous Steroids Therapy in Graves’ Ophthalmopathy
source: The British Journal of Ophthalmology
year: 2015
authors: Xing L, Ye L, Zhu W, Shen L, Huang F, Jiao Q, Zhou X, Wang S, Wang W, Ning G
summary/abstract:Background:
Previous studies have shown that smoking is closely related to the occurrence, severity and response to orbital radiation in Graves’ ophthalmopathy (GO). The aim of this study was to investigate whether smoking impacts the response to intravenous 4.5 g methylprednisolone therapy in patients with active moderate-to-severe GO.
Methods:
Ninety-two individuals with active moderate-to-severe GO who were treated with cumulative doses of 4.5 g intravenous methylprednisolone within 3 months were recruited. The patients were grouped as never smokers, active smokers (including smokers and quit smokers) and passive smokers.
Results:
We observed significantly greater response rate in never smokers compared with active smokers (73.9% vs 29.0%, p=0.001). After adjusting the confounding factors such as age, sex, body mass index, clinical activity score, thyroid-stimulating hormone receptor antibody and the duration of GO, smoking was independently associated with poor intravenous glucocorticoid (GC) response (OR 12.40, 95% CI 1.20 to 128.14, p=0.035). We also found the response rate was significantly higher in never smokers than in quit smokers (73.9% vs 16.7%, p=0.001), while no statistical significance between current smokers and quit smokers (36.8% vs 16.7%, p=0.228). There was a trend of poor response for passive smokers compared with never smokers (64.7% vs 72.2%, p=0.583).
Conclusions:
Smoking, even past smoking, was an independent risk factor associated with impaired response to intravenous corticosteroids in patients with GO. Smokers with GO should be given optimised treatment strategy such as higher dose of GC or combined radiation therapy.
DOI: 10.1136/bjophthalmol-2014-306463
read more
myBinderRelated Content
-
Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Gr...Background: High-dose intravenous gluco...
-
Graves’ Orbitopathy: Reevaluating Rundle’s CurveGraves’ orbitopathy (GO) is the most c...
-
Does Early Response to Intravenous Glucocorticoids Predict the Final Outcome in Patients With Moderate-To-Severe and...Purpose: Intravenous glucocorticoids (i...
-
Thyroid Eye DisordersWhat is the Thyroid? The thyroid is a b...
-
Ask a Doctor questions about Graves’ disease, thyroid eye disease, & Hashimoto’s thyroiditishttps://www.youtube.com/watch?v=RxElrnS6...
-
Selenium in Graves Hyperthyroidism and OrbitopathyPurpose: To review the in vitro and in ...
-
U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of LifeHorizon Therapeutics plc today announced...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google